Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study

Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study

BackgroundIntracranial hemorrhage (ICH) is a rare but serious side effect associated with the use of oral anticoagulants, such as dabigatran. The specific reversal agent for dabigatran, idarucizumab, is available for the management of individuals with ICH. The aim of this study was to provide real-w...

Full description

Bibliographic Details
Main Authors: Nils Kuklik, Anika Hüsing, Andreas Stang, Marcus Brinkmann, Christoph C. Eschenfelder, Christian Weimar, Hans-Christoph Diener
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Neurology
Subjects:
intracranial hemorrhage
anticoagulation
dabigatran
idarucizumab
vitamin-K-antagonists
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2023.1212495/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2023.1212495/full

Similar Items